ROCKET PHARMACEUTICALS, INC. Cash Flow Statement
RCKT|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
ROCKET PHARMACEUTICALS, INC. used $210M in operating cash flow and negative free cash flow of $216M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.68 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$258.7M | -$221.9M | -$169.1M | -$139.7M | -$77.3M | -$74.5M | -$74.5M | -$7.6M |
| Depreciation & Amortization | $7.2M | $3.9M | $3.2M | - | - | $330.0K | $330.0K | $67.0K |
| Operating Cash Flow | -$209.7M | -$178.1M | -$121.2M | -$74.6M | -$64.7M | -$53.8M | -$53.8M | -$5.5M |
| Capital Expenditures | $5.9M | $8.4M | $7.6M | $20.6M | $23.3M | $1.5M | $1.5M | $335.0K |
| Free Cash Flow | -$215.6M | -$186.5M | -$128.8M | -$95.2M | -$87.9M | -$55.2M | -$55.2M | -$5.8M |
| Share Buybacks | - | - | - | - | $0 | $0 | $668.0K | $0 |